Lancet publishes paper on the Visby Medical point-of-care PCR technology
A study of the performance of the Visby Medical Sexual Health Test, a single-use, point-of-care PCR device.
What is PCR?
PCR’s superpower lies in its super sensitivity, which enables it to sniff out even low levels of a pathogen in minutes. Here’s how it works.
Visby Medical’s Personal PCR Receives Funding from National Institute of Health, RADx Program
Visby Medical, an infectious disease diagnostic company, received funding from the National Institutes of Health as part of the organization’s Rapid Acceleration of Diagnostics (RADx) program, an initiative that aims to combat SARS-CoV-2 and increase national testing capacity for COVID-19.
Personal PCR: Rapid, Reliable, and Prolific
Personal PCR could one day become as common as the common cold. In the future, the device will deliver lab accurate results anywhere and to anyone — forever changing our relationship with diagnostics.
Visby Medical’s Personal PCR Device Receives FDA Emergency Use Authorization for Moderate-Complexity Lab Environments
Seven-year-old startup emerges from stealth mode, provides adaptable and rapid testing technology to frontline lab personnel fighting the pandemic
Visby exits stealth to bring its Personal PCR Test to the fight against COVID-19
Now that Visby has received EUA for our Personal PCR Test to be deployed in moderate-complexity CLIA-certified labs, we’re taking it to the front line of the fight against COVID-19. Each device is personal to individual patients, with results delivered to a lab technician in less than 30 minutes.
Rapid diagnostic for gonorrhea wins $19 million federal prize competition to combat antibiotic resistance
As appeared in NIH website 8/5/20
